

Special Issue

Human Cytomegalovirus: Recent Advances, Novel Targets and Vaccines

Message from the Guest Editors

Human cytomegalovirus (HCMV) is the most common infectious cause of congenital malformations, with developmental delay, sensorineural hearing loss and fetal death in 10–15% of cases. HCMV can also cause severe disease in immunocompromised patients (HIV positive and solid organ transplant or hematopoietic stem cell transplant recipients). Currently, there is no approved vaccine for the prevention of CMV infection. Three major molecules, ganciclovir (GCV), cidofovir (CDV) and foscarnet (FOS), all targeting the HCMV polymerase pUL54, are routinely used for prevention and treatment of HCMV infection in the transplant setting. In these patients, emergence of CMV drug-resistance is a growing therapeutic challenge, and these drugs are not recommended for administration in pregnant women. Developing low toxicity drugs and vaccines are accordingly a major public health priority. This Special Issue focuses on the recent development of novel targets, HCMV drugs, on existing vaccines in development, and recent novel advances such as mRNA prophylactic vaccines.

Dr. Gaëtan Ligat

Guest Editors

Dr. Sébastien Hantz

RESINFIT, CHU Limoges, Inserm, University of Limoges, UMR_S1092, 87000 Limoges, France

Dr. Gaëtan Ligat

Infinity, Toulouse Institute for Infectious and Inflammatory Diseases, INSERM UMR1291, CNRS UMR5051, Toulouse University, CEDEX 3, 31024 Toulouse, France

Deadline for manuscript submissions

closed (31 December 2022)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/83974

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).